MedPath

The efficacy of anti – toxoplasma drugs in the treatment of schizophrenia , a triple – blind, randomized , placebo-controlled clinical trial

Phase 2
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT201303287373N4
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Inclusion criteria :informed written consent ;diagnosis of schizophrenia according to DSMIV _TR criteria and clinical interview by psychiatrist ;a score of at least 60 in PANSS;age range 15-55
Exclusion criteria: pregnancy ; lactation ;substance abuse; severe physical disease ; contraindication of cotrimoxazole

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PANSS. Timepoint: before intervention and every 2 weeks. Method of measurement: clinical examination.
Secondary Outcome Measures
NameTimeMethod
Extrapyramidal and skin side effects. Timepoint: befor intervention and every 2 weeks. Method of measurement: clinical examination.
© Copyright 2025. All Rights Reserved by MedPath